TMCnet News
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Keynote at 2015 TERMIS World CongressInVivo Therapeutics Holdings Corp. (NVIV) has announced that Co-Founder Robert Langer, Sc.D., will make a keynote address and highlight InVivo's scientific progress at the 2015 Tissue Engineering & Regenerative Medicine International Society (TERMIS) World Congress in Boston on Wednesday, September 9, 2015. On the same day, Alex Aimetti, Ph.D., Senior Director, Medical Education and Scientific Support at InVivo, will participate in a clinical translation panel titled "Strategies for Translating Promising Academic Tissue Engineering Concepts to Successful Products." Other panelists include David Kaplan, Ph.D., from Tufts University, Stephen Badylak, D.V.M, Ph.D., M.D., from the McGowan Institute for Regenerative Medicine, Joachim Kohn, Ph.D., from Rutgers University, and Anthony Weiss, Ph.D., from the University of Sydney. Mark Perrin, InVivo's CEO and Chairman, said, "We are always honored to have Dr. Langer review our progress with the scientific community. It is also rewarding to have one of our senior team members selected to participate in a clinical translation panel." About the Neuro-Spina Scaffold Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple (News - Alert) Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company's investigational Neuro-Spinal Scaffold received the 2015 Becker's Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005431/en/ |
